Next –generation Supermicro AMD Helios platform to be showcased at ComputexRack-scale DCBBS architecture enables rapid deployment and seamless scaling from single racks to hyperscale...
Next –generation Supermicro AMD Helios platform to be showcased at ComputexRack-scale DCBBS architecture enables rapid deployment and seamless scaling from single racks to hyperscale...
Acquisition strengthens Ricoh's position as an end-to-end workplace services integrator across the Asia-Pacific regionTOKYO, June 2, 2026 /PRNewswire/ -- Ricoh Company, Ltd. and Ricoh Asia...
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical...
Line-fit integration of the Viasat Hybrid SATCOM Approach for the C-130J presents opportunity to expand high-capacity, resilient connectivity across multi-mission airlift operations
Line-fit integration of the Viasat Hybrid SATCOM Approach for the C-130J presents opportunity to expand high-capacity, resilient connectivity across multi-mission airlift operations
EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 58,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
BERLIN, Aug. 15, 2025 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, has received the highest possible ranking for consumer satisfaction from...
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...
CHICAGO, Aug. 14, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that registration for the 22nd annual CME Group University...
New agreement will help meet the growing demand for high-performance formulations in polyurethane, coatings, and adhesives production in the United States and Canada
DOWNERS GROVE,...